PPD Selected as Exclusive Partner by DiabetesAmerica  

PPD, Inc. (Nasdaq: PPDI) today announced it has entered into an exclusive alliance with DiabetesAmerica™, a provider of comprehensive diabetes care services based in Houston, Texas. Under the agreement, PPD will provide clinical research training and support to more than 20 clinical trial investigators who will conduct type 1 and type 2 diabetes clinical trials from DiabetesAmerica’s 17 centers across Texas and Arizona.

In return, DiabetesAmerica will work exclusively with PPD to provide clinical research services for endocrine and metabolic disease development programs over a minimum of three years. The agreement expands PPD’s ability to recruit for diabetes-related clinical trials through the use of DiabetesAmerica’s 16,000-plus patient database.

"Diabetes is a disease with serious complications that affects more than 23 million Americans,” said Mike Wilkinson, executive vice president of clinical development at PPD. "We are pleased to assist these physicians in bringing cutting-edge diabetes treatments to their patients through training and support. In addition, DiabetesAmerica’s patient database expands our ability to offer clinical trial options to a broader population of people living with this increasingly common disease.”

Founded in 2004, DiabetesAmerica currently treats nearly 20,000 patients with type 1 and type 2 diabetes. It offers a unique, comprehensive approach to diabetes treatment, with each of its health centers providing personalized medical care and education, nutrition and lifestyle needs at the same facility by a dedicated, experienced team of medical, nutrition and nursing professionals.

"DiabetesAmerica is committed to delivering the latest treatments in diabetes care to our patients,” said Rosemary Mazanet, M.D., Ph.D., and CEO of DiabetesAmerica. "Our alliance with PPD will help ensure our physicians are fully trained on managing drug development programs so we can continue to bring complete diabetes care to our patients.”

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 38 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about PPD’s exclusive partnership with DiabetesAmerica, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: risks associated with and dependence on collaborative relationships; the ability to attract and retain key personnel; competition within the outsourcing industry; success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.